SABS (SAB Biotherapeutics) Construction In Progress: $0.41 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SABS SAB Biotherapeutics Inc SABS
26 GF Score
Price $3.90
! 2 Warning Signs
View Full Analysis

What is SAB Biotherapeutics Construction In Progress?

SAB Biotherapeutics SABS +1.56% 26 Construction In Progress is $0.41 Mil as of Jun. 2026. GuruFocus rates SABS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

SAB Biotherapeutics's quarterly construction in progress increased from Dec. 2025 ($0.76 Mil) to Mar. 2026 ($1.44 Mil) but then declined from Mar. 2026 ($1.44 Mil) to Jun. 2026 ($0.41 Mil).

SAB Biotherapeutics's annual construction in progress stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.76 Mil).

SAB Biotherapeutics Construction In Progress Historical Data

* Premium members only.

The historical data trend for SAB Biotherapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SAB Biotherapeutics Construction In Progress Chart

SAB Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial 4.61 0.31 0.00 0.00 0.76

SAB Biotherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.76 1.44 0.41
SABS
26GF Score
SAB Biotherapeutics Inc SABS
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SAB Biotherapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.41 Mil mean?
SAB Biotherapeutics (SABS) has a Construction In Progress of $0.41 Mil as of Jun. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on SAB Biotherapeutics and its competitors.
Is SAB Biotherapeutics' Construction In Progress too high?
SAB Biotherapeutics' current Construction In Progress is $0.41 Mil. Overall, SAB Biotherapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' Construction In Progress compare to SLGL and BCYC?
SAB Biotherapeutics' Construction In Progress of $0.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on SAB Biotherapeutics and its competitors. SAB Biotherapeutics's current Construction In Progress is $0.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current Construction In Progress of $0.41 Mil. The current Construction In Progress is $0.41 Mil. SAB Biotherapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current Construction In Progress is $0.41 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SAB Biotherapeutics Business Description

Address 777 West 41st Street, Suite 401, Miami Beach, FL, USA, 33140
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
26GF Score

Get the complete analysis for SABS

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.90
Price